Marijuana Lozenge Patented by Cannabis Sativa

MESQUITE, NV / ACCESSWIRE / October 15, 2018 / Cannabis Sativa, Inc. (CBDS) is pleased to announce that the United States Patent Office will issue to CBDS the US Patent number 10105343 titled "Cannabis based compositions and methods of treating hypertension" on October 23, 2018.

"We are excited to see the patent finally get issued", said CEO Mike Gravel. "Cannabis Sativa made a bold deal acquiring this pending IP in the merger acquisition of Kush in 2014, which included Kubby Patent and Licenses. This lozenge patent is the second patent to be granted resulting from that agreement, following the December 2016 issuing of our patented marijuana strain, Ecuadorian Sativa."

"This coconut oil based lozenge is unique because of its rapid onset and long term effects, and is based on our patented strain of cannabis, Ecuadorian Sativa", stated President David Tobias.

The invention relates to a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery comprising a pharmaceutically acceptable base and an effective amount of at least one cannabinoid or endocannabinoid containing extract of a cloned hybrid of the plant Cannabis sativa, subspecies sativa and Cannabis sativa, subspecies indica of the CTSX-ISS lineage.

Cannabis Sativa plans on developing the lozenge through partnering with a California licemse holder and subsequent licensing agreements. "We envision entering into the marketplace in the San Francisco Bay market, where this lozenge was conceived and well received in the pioneering days of legalized medical marijuana", Tobias continued. "These patents help greatly in standardizing the development of our intellectual properties."

This patent was filed April 30, /2010 by Steve Kubby. The Company pays homage to his vision and foresight.

About Cannabis Sativa, Inc.:

Cannabis Sativa, Inc. (''CBDS'') is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the ''hi'' and ''White Rabbit'' brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, owns patent pending and trade secret formulas and processes, offers the hi benefits discount pharmacy card, and operates subsidiaries including: PrestoDoctor® (https://prestodoctor.com), Wild Earth Naturals®, (https://wildearthnaturals.com/), and iBudtender (https//:ibudtender.com). In addition, CBDS seeks strategic partners for acquisition of operating companies, intellectual property and other assets which fit within the CBDS corporate vision.

Forward-Looking Statements:

This press release contains ''forward-looking statements.'' Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company's success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contact Information:

Investor Relations
1646 West Pioneer Blvd Suite 120
Mesquite, NV 89027
702-346-3906
http://www.cannabissativainc.com

SOURCE: Cannabis Sativa, Inc.